Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 15/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761651 | 0.88 | RPS6KA5 (0.67) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4716326 | 0.86 | RPS6KA5 (0.78) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4718298 | 0.86 | RPS6KA5 (0.82) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4760126 | 0.86 | RPS6KA5 (0.64) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4760551 | 0.85 | RPS6KA5 (0.63) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4718283 | 0.84 | RPS6KA5 (0.68) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4715083 | 0.84 | RPS6KA5 (0.68) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4718289 | 0.84 | RPS6KA5 (0.68) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4714283 | 0.84 | RPS6KA5 (1.00) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4714865 | 0.84 | RPS6KA5 (0.66) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | claimed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | RPS6KA5 117/4885DYRK1A 470/4885RPS6KB1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.